BCHE and amyloidosis: Memantine, an N-methyl-d-aspartate receptor (NMDAR) antagonist, is clinically quite effective for behavioral symptoms and is often added to cholinesterase inhibitors to enhance their effects, whereas aducanumab has recently been approved for amyloidosis (Langa et al., 2004; Giacobini et al., 2022).